Novartis ($NVS), in the midst of a long-running effort to make clinical trials more efficient, has recruited Qualcomm ($QCOM) to help it gather and store patient data from medical devices. Under the deal, Qualcomm will provide its 2net platform to Novartis, allowing the drugmaker to continually monitor the biometrics of clinical trial participants, storing data in a cloud-based system. More